Back to results
US 11,446,334 B2Granted
Use of term amniotic fluid cells for the treatment of acute and chronic respiratory diseases
AssigneeAmniotics AB
InventorsJan Talts, Niels-Bjarne Woods, Kare Engkilde, Marcus Larsson
Life of this patent
Estimating the term…
Abstract
Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity are for in production of advanced therapeutic medicinal products. In certain examples, term amniotic fluid derived cells having characteristics of lung cells can be isolated. In some the term amniotic fluid derived cells having characteristics of lung cells can be used in the treatment of acute and chronic respiratory diseases.
Claims8
A method of treating acute respiratory distress syndrome in a patient in need thereof, comprising:
- performing adherence selection on term amniotic fluid (TAF) cells to obtain TAF adherence cells;
- passaging the TAF adherence cells to obtain TAF mesenchymal stem cells (TAF MSCs);
- selecting TAF MSCs that express Endosialin to obtain lung TAF MSCs;
- and
- administering the lung TAF MSCs to the patient.
2 more elements
Dependencies are inferred from the claim text.